Article
Clinical Neurology
Eugen Trinka, Taoufik Alsaadi, Hiroko Goji, Taketoshi Maehara, Satoru Takahashi, Julia Jacobs, Rosaria Renna, Francisco Jose Gil-Lopez, Rob McMurray, Ricardo Sainz-Fuertes, Vicente Villanueva
Summary: This study aimed to evaluate the effectiveness and tolerability of PER in the treatment of idiopathic generalized epilepsy under real-world conditions. The results showed that PER had good effectiveness and tolerability in people with idiopathic generalized epilepsy in clinical practice, consistent with clinical trial evidence.
Article
Behavioral Sciences
James Wheless, Robert T. Wechsler, Patricia Penovich, Eric Segal, Michael Chez, Antonietta Coppola, Anita Datta, Wendyl D'Souza, Imad Najm, Sheri Cappucci, Ricardo Sainz-Fuertes, Vicente Villanueva
Summary: In this study, the largest pooled analysis of PER clinical practice data conducted to date, PER was shown to be effective and generally well tolerated when used to treat people with focal or generalized epilepsy in everyday clinical practice, regardless of age category. No new or unexpected side effects emerged following long-term use in the real-world setting.
EPILEPSY & BEHAVIOR
(2023)
Article
Clinical Neurology
Yotin Chinvarun, Rafael Toledano Delgado, Alexandra Astner-Rohracher, Tim Wehner, Manuel Toledo, Sara Matricardi, Eugen Trinka, Manoj Malhotra, Oliver Shastri, Vicente Villanueva
Summary: This study investigated the effectiveness, safety, and tolerability of perampanel monotherapy in treating focal or generalized epilepsy in clinical practice. The results showed that perampanel was effective as monotherapy, especially for generalized-onset seizures, and had good tolerability and safety.
ACTA NEUROLOGICA SCANDINAVICA
(2023)
Article
Clinical Neurology
Vicente Villanueva, Wendyl D'Souza, Hiroko Goji, Dong Wook Kim, Claudio Liguori, Rob McMurray, Imad Najm, Estevo Santamarina, Bernhard J. Steinhoff, Pavel Vlasov, Tony Wu, Eugen Trinka
Summary: The PERAMPANEL pooled analysis of effectiveness and tolerability study showed that PER is effective and generally well tolerated when used to treat people with focal and/or generalized epilepsy in everyday clinical practice.
JOURNAL OF NEUROLOGY
(2022)
Review
Pediatrics
Ahmed Elmardenly, Zekra Aljehani, Abdullah Tamim, Anas Alyazidi, Osama Muthaffar
Summary: This study aimed to evaluate the safety and efficacy of perampanel (PER) as an adjuvant treatment for children with drug-resistant epilepsy. The results showed that PER demonstrated good effectiveness and tolerability in the treatment of drug-resistant epilepsy.
Article
Pharmacology & Pharmacy
Tao Yu, Zi-Teng Teng, Xue-Yan Liu, Hua Wang
Summary: This study investigated the therapeutic effect and influencing factors of perampanel (PER) on electrical status epilepticus during sleep (ESES). The results showed that PER add-on treatment had a good therapeutic effect on ESES and was not dose-dependent. However, a longer duration of ESES was associated with a worse therapeutic effect.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Clinical Neurology
Ranran Zhang, Shan Qiao, Xiqin Fang, Kemo Wang, Yanting Shi, Qianwen Du, Tingting Yang, Xuewu Liu
Summary: The study demonstrated the efficacy and tolerability of adjunctive PER in Chinese patients with focal-onset seizures, with response rates of 60% and 71.1% at 3 and 6 months, respectively. However, the freedom of seizures at the same points was relatively low.
FRONTIERS IN NEUROLOGY
(2021)
Article
Clinical Neurology
Chenmin He, Cong Chen, Yuyu Yang, Lingli Hu, Bo Jin, Wenjie Ming, Zhongjin Wang, Yao Ding, Meiping Ding, Shuang Wang, Shan Wang
Summary: This study evaluated the clinical characteristics and prognostic significance of subclinical seizures in patients who underwent epilepsy surgery. The study found that the rate of subclinical seizures captured on intracranial EEG monitoring was higher than that on scalp EEG monitoring. Subclinical seizures detected on scalp EEG were associated with younger seizure onset, while those detected on intracranial EEG were associated with temporal lobe epilepsy and predicted surgical outcomes in focal epilepsy.
NEUROLOGY AND THERAPY
(2022)
Review
Pharmacology & Pharmacy
Liyan Hou, Jingjing Yang, Xuan Zhang, Na Li, Sheng Li, Lei Zhang, Jie Zhao, Qingshan Wang
Summary: This study systematically reviewed the efficacy and tolerability of perampanel (PER) in the treatment of epilepsy. The results showed that PER was effective in reducing seizures and was well tolerated. However, adverse effects were reported in a significant number of patients and withdrawal rates were relatively high.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Medicine, General & Internal
Roshan K. Babar, Rebecca Bresnahan, Conor S. Gillespie, Benedict D. Michael
Summary: Lacosamide is effective and well-tolerated as add-on treatment for drug-resistant focal epilepsy in the short term. It can increase the number of patients with a 50% or greater reduction in seizure frequency and potentially increase seizure freedom. However, higher doses of lacosamide may lead to higher rates of adverse events and treatment withdrawal. Further research is needed to evaluate the use of lacosamide in children and its long-term efficacy and tolerability.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2021)
Article
Clinical Neurology
Claudio Liguori, Estevo Santamarina, Adam Strzelczyk, Juan Jesus Rodriguez-Uranga, Rohit Shankar, Xiana Rodriguez-Osorio, Stephane Auvin, Paolo Bonanni, Eugen Trinka, Rob McMurray, Ricardo Sainz-Fuertes, Vicente Villanueva
Summary: The PERMIT study is the largest analysis of perampanel clinical practice data. The results showed that early add-on therapy with perampanel was more effective and better tolerated compared to late add-on therapy.
FRONTIERS IN NEUROLOGY
(2023)
Article
Behavioral Sciences
Pablo Alonso-Singer, Maria J. Aguilar-Amat Prior, Javier Oliva-Navarro, Andreu Massot-Tarrus, Beatriz G. Giraldez, Pedro Bermejo, Maria DeToledo-Heras, Angel Aledo-Serrano, Elena Martinez-Cayuelas, Pilar Tirado-Requero, Ramon Velazquez-Fragua, Gloria Lopez-Sobrino, Joaquin Ojeda
Summary: This study provides real-world evidence on the safety and efficacy of perampanel in patients with DEEs, especially in controlling GTCS, TS, and FOS seizure types.
EPILEPSY & BEHAVIOR
(2022)
Article
Clinical Neurology
Simona Lattanzi, Giovanni De Maria, Eleonora Rosati, Giuseppe Didato, Valentina Chiesa, Federica Ranzato, Laura Canafoglia, Edward Cesnik, Francesca Anzellotti, Stefano Meletti, Giada Pauletto, Annacarmen Nilo, Emanuele Bartolini, Daniela Marino, Elena Tartara, Concetta Luisi, Paolo Bonanni, Alfonso Marrelli, David Stokelj, Filippo Dainese, Nicoletta Foschi, Claudia Cagnetti, Stefano Gazzina, Margherita Contento, Martina Biggi, Matteo Magliani, Roberta Di Giacomo, Chiara Pastori, Maria Paola Canevini, Elena Zambrelli, Giuseppe Billo, Marina Casazza, Elisa Fallica, Giuseppa Rosa, Fedele Dono, Rino Speranza, Cristina Cioclu, Anna Elisabetta Vaudano, Lorenzo Kiferle, Rosita Galli, Martina Guadagni, Carlo Andrea Galimberti, Benedetta Kassabian, Florinda Ferreri, Elisa Osanni, Roberta Ciuffini, Valeria Badioni, Simone Beretta
Summary: This study assessed the clinical response to add-on brivaracetam (BRV) in real-world practice and found that BRV improved seizure control in patients with focal epilepsy. Prior antiseizure medications and baseline monthly seizure frequency were independently associated with the primary endpoint.
Article
Behavioral Sciences
Rui Zhou, Rui Qu, Min Liu, Dan-Ping Huang, Jin-Yi Zhou, Yan Chen, Xu-Qin Chen
Summary: This study aimed to investigate the efficacy, tolerability, and effect on behavior and emotion of PER and LCM as monotherapy in pediatric patients with newly diagnosed focal epilepsy. The results showed that PER and LCM had similar effectiveness and tolerability as monotherapy, and did not have a significant impact on behavior and emotion. Rating: 8/10.
EPILEPSY & BEHAVIOR
(2023)
Article
Public, Environmental & Occupational Health
Donger Zhang, Xia Li, Jing Ding, Xiatong Ke, Wenpei Ding, Yinan Ren, He Xu, Hongchao Li, Aixia Ma, Wenxi Tang
Summary: The study demonstrates that Perampanel is cost-effective for Chinese patients with partial-onset seizures, improving patient outcomes and quality-adjusted life years while maintaining an acceptable budget impact on medical insurance.
FRONTIERS IN PUBLIC HEALTH
(2021)